EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

BofA lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $88 and keeps a Buy rating on the shares after the company ...

Exact Sciences (NASDAQ:EXAS – Get Free Report) had its price target boosted by stock analysts at Canaccord Genuity Group from ...

Shares of Exact Sciences Co. (NASDAQ:EXAS – Get Free Report) gapped down prior to trading on Wednesday after the company ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tycho ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

These ratings convey expectations for the relative performance of Exact Sciences compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future value.

On Friday, Exact Sciences Corp (EXAS) stock saw a decline, ending the day at $69.11 which represents a decrease of $-1.15 or -1.64% from the prior close of $70.26. The stock opened at $70.2 and ...